Studies find GLP-1 OSA benefits, no weight loss gap between diet beverages and water

Two recently published clinical studies report findings on obstructive sleep apnea treatment and long term weight outcomes.

Stands on 3 placed sources from 2 publishers.

Researchers study sleep apnea treatment options AI illustrationhow this picture was made

Two separate published studies have reported new findings relevant to clinical weight and sleep management. A research review published 2025-09-03 in JAMA Otolaryngology found that GLP-1 receptor agonists may offer significant improvement in obstructive sleep apnea related to obesity ^[1]. Zepbound, or tirzepatide, is currently the only weight loss medication that holds FDA approval for the treatment of moderate to severe obstructive sleep apnea in adults with obesity ^[2]. A 2026 randomized controlled trial published in the British Journal of Nutrition found no statistically significant difference in two year weight loss between participants drinking diet beverages and those drinking water ^[3].

Proof3 sources · 2 publishers · signed

What this stands on

A research review published in JAMA Otolaryngology on 2025-09-03 found that GLP-1 receptor agonists may offer significant improvement in obstructive sleep apnea (OSA) related to obesity. · Healthline Media
Zepbound (tirzepatide) is currently the only weight loss medication that is FDA approved for the treatment of moderate to severe OSA in adults with obesity. · Healthline Media
A 2026 randomized controlled trial published in the British Journal of Nutrition found no statistically significant difference in two year weight loss between participants drinking diet beverages and those drinking water. · News-Medical

We could not place any of them by their address. None is an official body: that part stands on reporting, not on the underlying document or transcript.